METHODS OF PRODUCING PANCREATIC HORMONES
First Claim
Patent Images
1. A method for producing insulin, said method comprising the steps of:
- (a) contacting human embryonic stem (hES) cells in vitro with a first medium comprising an agent that activates a TGF-β
receptor family member;
(b) culturing in vitro the hES-derived cells of step (a) in a second medium lacking the agent that activates the TGF-β
receptor family member;
(c) transplanting the hES-derived cells of step (b) into a mammalian subject; and
(d) maturing the hES-derived cells of step (c) in vivo, thereby obtaining insulin secreting cells.
2 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.
47 Citations
20 Claims
-
1. A method for producing insulin, said method comprising the steps of:
-
(a) contacting human embryonic stem (hES) cells in vitro with a first medium comprising an agent that activates a TGF-β
receptor family member;(b) culturing in vitro the hES-derived cells of step (a) in a second medium lacking the agent that activates the TGF-β
receptor family member;(c) transplanting the hES-derived cells of step (b) into a mammalian subject; and (d) maturing the hES-derived cells of step (c) in vivo, thereby obtaining insulin secreting cells. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A method for producing insulin, said method comprising the steps of:
-
(a) contacting human embryonic stem (hES) cells in vitro with a medium comprising an agent that activates a TGF-β
receptor family member(b) culturing in vitro the hES-derived cells of step (a) in a second medium comprising a second agent that inhibits the TGF-β
receptor family member;(c) transplanting the hES-derived cells of step (b) into a mammalian subject; and (d) maturing the hES-derived cells of step (c) in vivo, thereby obtaining insulin secreting cells. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20)
-
Specification